Legend Biotech Q2 FY26 turns to net income of $33.2 million; revenue rises 51.9% to $387.5 million year over year

Reuters2026/08/11 11:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Legend Biotech posted IFRS net income of $33.2 million, swinging from a loss, on total revenue of $387.5 million.
CARVYKTI net trade sales rose 50% year over year to about $657 million, with U.S. growth of 32% and ex-U.S. growth of 128%.
IFRS operating income improved to $57.7 million, reversing an operating loss, as collaboration revenue climbed to $326.1 million.
Balance sheet strengthened with $212 million in net proceeds from a 7,700,000-ADS offering; cash, cash equivalents and time deposits totaled about $965 million.
Interim CEO Alan Bash cited continued CARVYKTI momentum and first proof-of-concept for in vivo CAR-T LB2501, reporting 100% ORR and 83.3% CR at DL2.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Legend Biotech Q2 FY26 turns to net income of $33.2 million; revenue rises 51.9% to $387.5 million year over year

You may also like

Crypto prices